Karyopharm Therapeutics Inc.
Commercial‑stage oncology biotech Karyopharm develops selective nuclear‑export inhibitors (Selinexor, XPOVIO) treating multiple myeloma, DLBCL, and solid tumors; partnerships with Menarini, Antengene, BMS boost therapy portfolio and revenue growth.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 279
- HQ: Newton
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.